HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

Dana Horakova, Robert Zivadinov, Bianca Weinstock-Guttman, Eva Havrdova, Miriam Tamaño-Blanco, Michaela Tyblova, Sara Hussein, Niels Bergsland, Laura Willis, Jan Krasensky, Manuela Vaneckova, Zdenek Seidl, Petra Lelkova, Murali Ramanathan

Research output: Contribution to journalArticlepeer-review


Objectives: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed.The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. Methods: We genotyped 205 CIS patients (age: 29.0 ± 7.7. years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4. months of the initial demyelinating event. Results: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p

Original languageEnglish
Pages (from-to)76-80
Number of pages5
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Jul 2011


  • Clinically isolated syndromes
  • Genetics
  • HLA
  • MRI
  • Multiple sclerosis
  • Progression

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology


Dive into the research topics of 'HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event'. Together they form a unique fingerprint.

Cite this